Toggle light / dark theme

Synthetic DNA toolkit expands scientists’ ability to recognize genetic targets

A new method for recognizing and targeting DNA that dramatically expands the range of genetic sequences scientists can identify has been developed by experts at the University of Portsmouth. Published this week in Nature Communications, the research opens new possibilities for gene-targeting technologies, molecular diagnostics and DNA nanotechnology.

Dr. David Rusling, associate professor in bioengineering from the University of Portsmouth’s School of Medicine, Pharmacy and Biomedical Sciences, said, Our lab develops synthetic molecules that can recognize and bind to unique gene sequences. By introducing synthetic DNA bases into these molecules, we’ve been able to significantly improve how they recognize their targets.

I’ve worked in this area for around 20 years, and this is the first time we’ve had a system that combines strong recognition under physiological conditions with building blocks that are commercially available to other researchers.

An AAV variant selected through NHP screens robustly transduces the brain and drives secreted protein expression in NHPs and mice

Tecedor et al. used directed evolution to engineer AAVs with enhanced ependymal and brain delivery after injection into the cerebrospinal fluid. I think it would be interesting to try lumbar puncture delivery of these AAVs as well to see if they maintain decent biodistribution. (See my other post about Hinderer et al.’s paper: https://doi.org/10.1016/j.omtm.2020.04.012).


AAV capsid variants enriched for transduction of ventricular lining cells and brain parenchyma reduce the dose required for gene therapy to the CNS.

Specific cognitive abilities are highly heritable independent of general intelligence

A massive new meta-analysis reveals that individual cognitive abilities, like reading and math, rely on inherited DNA just as much as overall intelligence, suggesting people possess heavily customized genetic cognitive profiles independent of general smarts.

These tiny genetic fragments may be critical for telling a brain when to rest

The altered presence of tiny fragments of neuronal genes, called microexons, causes hyperarousal in zebrafish. This is the main conclusion of an international study led by Pompeu Fabra University (UPF) and the Center for Genomic Regulation (CRG). An abnormal pattern of neural microexon presence leads to a hyperarousal state characterized by heightened neural activity and insomnia, commonly associated with stress but also with neurodevelopmental disorders.

Arousal regulation is highly conserved in evolution. Therefore, this finding could help researchers understand the mechanism underlying some human neurodevelopmental disorders, such as autism and schizophrenia, conditions associated with microexon mutations.

To survive, animals need to be ready to react to external and internal stimuli. This activation of the central nervous system, arousal, is highly conserved throughout the animal kingdom.

Gene therapy shows promise in ARC syndrome, a deadly childhood liver disease

A new gene therapy has been used to successfully treat a deadly childhood liver disease in mice that model the disease, according to researchers at UCL and Great Ormond Street Hospital. Arthrogryposis, renal dysfunction and cholestasis (ARC) syndrome is a lethal genetic disorder usually caused by a lack of the VPS33B protein, with children diagnosed with the condition rarely living beyond their first year of life.

Now, in a study published in Nature Communications, the UCL-GOSH team found that by injecting a healthy version of the gene into the body, they can treat the condition in mice lacking VPS33B. Crucially, the final version of the treatment, which specifically targeted the liver cells, caused no harm. In the earlier versions, the genes became abnormally activated and caused cancerous cells to grow and expand in some cases.

While more tests must be done before the treatment can be tested in humans, the researchers’ breakthrough offers hope to babies with this devastating disorder and their families. In the UK, as many as six pregnancies per year might be affected by ARC syndrome. Furthermore, the findings may promote improved understanding of why some treatments may cause cancer.

/* */